UNITEDHEALTH GROUP INCORPORATED (Delaware) (UNH) Stock News

News

• 

  Benzinga ‧ 2026/11/13

  UnitedHealthcare Policy Assessment Urges Clearer Provider Guidance

  External consultants praise UnitedHealthcare's evidence-based medical policy process while recommending clearer templates and documentation.

  Read Full Article

  • 
    UNH$407.48+0.58%
  • 
    FCN$202.68+2.11%
• 

  Benzinga ‧ 2026/11/12

  If You Invested $1000 In UnitedHealth Group Stock 20 Years Ago, You Would Have This Much Today

  UnitedHealth Group (NYSE:UNH) has outperformed the market over the past 20 years by 2.67% on an annualized basis producing an average annual return of 11.45%. Currently, UnitedHealth Group has a market capitalization of

  Read Full Article

  • 
    UNH$407.48+0.58%
• 

  Massive ‧ 2026/11/12

  Why Is UnitedHealth (UNH) Up 1.9% Since Last Earnings Report?

  UnitedHealth Group (UNH) reported Q3 2026 adjusted EPS of $4.69, beating consensus estimates of $4.12, with a 60.6% year-over-year increase. The company raised its 2026 adjusted EPS guidance to at least $20.5 from the previous range of $19.5-$20, driven by improved medical cost management and strong performance from Optum Insight and Optum Rx. Despite a slight revenue decline of 0.4% year-over-year to $112.7 billion, the company improved its medical care ratio to 88.4% and generated strong operating cash flows of $25.1 billion in the first nine months of 2026.

  Read Full Article

  • 
    UNH$407.48+0.58%
• 

  Massive ‧ 2026/11/12

  Is it Too Late to Buy UnitedHealth Stock?

  UnitedHealth Group has demonstrated strong management performance in correcting 2025 miscalculations, with earnings jumping 60% and guidance raised for the third time in the year. The article examines whether the stock remains a good investment opportunity despite its recent strong performance.

  Read Full Article

  • 
    UNH$407.48+0.58%
• 

  Massive ‧ 2026/11/12

  Can CVS Health's 2028 Split Unlock Value Despite Execution Risks?

  CVS Health announced plans to separate into two independent publicly traded companies by mid-2028: one retaining Aetna, Caremark, and care operations, and another housing retail pharmacies and MinuteClinic. The split aims to improve capital allocation and operating flexibility, though it carries execution risks, restructuring costs, and potential dis-synergies during the transition period.

  Read Full Article

  • 
    CVS$89.34-0.49%
  • 
    CI$296.93+0.25%
  • 
    UNH$407.48+0.58%
• 

  Massive ‧ 2026/11/11

  Can HUM's New Oncology Model Strengthen Its Value-Based Care Strategy?

  Humana Inc. has launched a new oncology care model in partnership with Evolent Health and American Oncology Network across eight states. The initiative streamlines prior authorization for qualifying practices, uses EHR analytics and provider scorecards to promote evidence-based cancer treatment, and aims to improve care coordination while reducing specialty care spending. HUM stock has rallied 82.2% over the past year but trades at a premium valuation of 29.08x forward P/E versus the industry average of 15.72x.

  Read Full Article

  • 
    HUM$450.28+1.42%
  • 
    UNH$407.48+0.58%
  • 
    ELV$429.63+0.49%
• 

  Massive ‧ 2026/11/11

  Is CVS Stock Worth Buying as Aetna Recovers but PBM Risks Persist?

  CVS Health is entering a more constructive earnings phase as Aetna's medical benefit ratio improves, pharmacy operating income rises 10.6%, and operating cash flow reaches $15.32 billion. However, persistent pressure from pharmacy benefit management, medical membership declines, and reimbursement headwinds keep execution risk elevated through 2027.

  Read Full Article

  • 
    CVS$89.34-0.49%
  • 
    CI$296.93+0.25%
  • 
    UNH$407.48+0.58%
• 

  Massive ‧ 2026/11/11

  UnitedHealth Just Raised Guidance for the Third Time This Year. Where Will the Stock Be in 3 Years?

  UnitedHealth Group has raised its 2026 earnings guidance for the third time this year, with adjusted EPS now targeted at $20.50, up from $17.75 in January. The company's turnaround is gaining momentum, driven by operational improvements in Optum Health and better medical cost management. Analysts project the stock could reach between $444 and $672 by 2029 based on 13-16% annual earnings growth, though regulatory scrutiny and rising medical costs remain risks.

  Read Full Article

  • 
    UNH$407.48+0.58%